A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
300actual
Sites
25
Countries
Canada, France, Germany +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-24 | actual | When the study began enrolling |
| Primary completion | 2026-04-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-22 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Drug: Cagrilintide
- Drug: Semaglutide
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFRelative change in body weight
measured From baseline (week 0) to end of treatment (week 68)
Achievement of ≥5% weight reduction
measured From baseline (week 0) to end of treatment (week 68)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed